Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00448058
Status:
COMPLETED
Last Update Posted:
2014-10-10
First Post:
2007-03-13
Brief Title:
A Study Of New Medicine GSK 372475 For The Treatment Of Depression
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Ten-Week Multicenter Randomized Double-Blind Placebo and Active-Controlled Parallel-Group Flexible-Dose Study Evaluating the Efficacy Safety and Tolerability of GSK372475 15 mgDay to 20 mgDay or Extended Release Venlafaxine XR 150 mgDay to 225 mgDay Compared to Placebo in Adult s
Status:
COMPLETED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy safety and tolerability of GSK372475 compared with placebo in the treatment of outpatient subjects with Major Depressive Disorder MDD
Detailed Description:
A Ten-Week Multicenter Randomized Double-Blind Placebo and Active-Controlled Parallel-Group Flexible-Dose Study Evaluating the Efficacy Safety and Tolerability of GSK372475 15 mgday to 20 mgday or Extended Release Venlafaxine XR 150 mgday to 225 mgday Compared to Placebo in Adult Subjects Diagnosed with Major Depressive Disorder
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None